Diabetes Research and Clinical Practice
Volume 64, Issue 1 , Pages 59-70 , April 2004

Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men

  • Noriyuki Nakanishi

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-6-6879-3911; fax: +81-6-6879-3919.
    • ,
  • Toshio Takatorige

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan
    • ,
  • Hideki Fukuda

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan
    • ,
  • Kokoro Shirai

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan
    • ,
  • Wenjuan Li

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan
    • ,
  • Mitsuharu Okamoto

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan
    • ,
  • Hiroshi Yoshida

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan
    • ,
  • Yoshio Matsuo

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan
    • ,
  • Kenji Suzuki

      Affiliations

    • Japan Labor and Welfare Association, 1-24-4 Ebisu, Shibuya-Ku, Tokyo 150-0013, Japan
    • ,
  • Kozo Tatara

      Affiliations

    • Department of Social and Environmental Medicine, Course of Social Medicine, Osaka University Graduate School of Medicine F2, 2-2 Yamada-oka, Suita-shi, Osaka 565-0871, Japan

Received 17 April 2003 ,Revised 25 July 2003 ,Accepted 9 October 2003.

References 

  1. World Health Organization, Obesity—Preventing and Managing the Global Epidemic, Report of a WHO Consultation, World Health Organization, Geneva, 2000 (Technical Report Series No. 894).
  2. Zimmet PZ. Kelly West Lecture 1991: challenges in diabetes epidemiology—from West to the rest. Diabetes Care. 1992;15:232–252
  3. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  4. Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol. Rev. 1998;20:157–172
  5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med. 1998;15:539–553
  6. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia. 1993;36:553–559
  7. Klein BEK, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 2002;25:1790–1794
  8. World Health Organization, WHO Expert Committee: Arterial Hypertension and Ischemic Heart Disease, Prevention Aspects, World Health Organization, Geneva, 1962 (Technical Report Series No. 231).
  9. G.A. Rose, H. Blackburn, Cardiovascular Survey Methods, World Health Organization, Geneva, 1968.
  10. The Ministry of Education Study Group, Characteristics of Stroke in Japan and Standardized Criteria for Stroke Diagnosis, The Ministry of Education, Tokyo, 1963 (in Japanese).
  11. Ad Hoc Committee on Cerebrovascular Disease of the National Institute of Neurological Disease and Blindness, A Classification and Outline of Cerebrovascular Disease, Neurology 8 (1958) 1–34.
  12. Nakanishi N, Yoshida H, Matsuo Y, Suzuki K, Tatara K. White blood-cell count and the risk of impaired fasting glucose or Type II diabetes in middle-aged Japanese men. Diabetologia. 2002;45:42–48
  13. Nakanishi N, Suzuki K, Tatara K. Alcohol consumption and risk for development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2003;26:48–54
  14. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20 (1997) 1183–1197.
  15. Targher G, Seidell JC, Tonoli M, Muggeo M, De Sandre G, Cigolini M. The white blood cell count, its relationship to plasma insulin and other cardiovascular risk factors in healthy male individuals. J. Intern. Med. 1996;239:435–441
  16. Marques-Vidal P, Mazoyer E, Bongard V, et al.  Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care. 2002;25:1371–1377
  17. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:455–461
  18. Kylin E. Studien über das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. Zentralblatt für innere Medizin. 1923;44:105–127
  19. UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ 317 (1998) 703–713.
  20. Pyörälä KK, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620
  21. The Diabetes Prevention Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med. 346 (2002) 393–403.
  22. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus, current management guidelines. Arch. Intern. Med. 2003;163:33–40
  23. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am. J. Epidemiol. 2002;156:1070–1077
  24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285 (2001) 2486–2497.
  25. Mykkänen L, Haffner SM, Kuusisto J, Pyörälä K, Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes. 1994;43:552–557
  26. Weinstock Brown W, Keane WF. Proteinuria and cardiovascular disease. Am. J. Kidney Dis. 2001;38(4 Suppl.):S8–S18
  27. Diercks GFH, van Boven AJ, Hillege JL, de Jong PE, Rouleau JL, van Gilst WH. The importance of microalbuminuria as a cardiovascular riks indicator, a review. Can. J. Cardiol. 2002;18:525–535
  28. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation, European Group for the Study of Insulin Resistance (EGIR). Diabetes Med. 1999;16:442–443
  29. Hodge AM, Dowse GK, Zimmet PZ. Microalbuminuria, cardiovascular risk factors, and insulin resistance in two populations with a high risk of type 2 diabetes mellitus. Diabetes Med. 1996;13:441–449
  30. Zavaroni I, Bonini L, Gasparini P, et al.  Dissociation between urinary albumin excretion and variables associated with insulin resistance in a healthy population. J. Intern. Med. 1996;240:151–156
  31. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286–1292
  32. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 1998;18:1199–1202
  33. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia. 1998;41:1241–1248
  34. E. Sim, Humoral Factors, IRL Press, Oxford, 1993.
  35. R.A. Memon, K.R. Feingold, C. Grunfeld, Cytokines and intermediary metabolism, in: D.G. Remick, J.S. Friedland (Eds.), Cytokines in health and disease, second ed., Marcel Dekker, New York, 1997, pp. 381–399.
  36. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999;340:448–454
  37. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int. J. Obes. Relat. Metab. Disord. 2001;25:1416–1420
  38. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334
  39. McLaughlin T, Abbasi F, Lamendola C, et al.  Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation. 2002;106:2908–2912
  40. Schmidt MI, Duncan BB, Sharrett AR, et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study), a cohort study. Lancet. 1999;353:1649–1652
  41. Freeman DJ, Norrie J, Caslake MJ, et al.  C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596–1600
  42. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia, the current status on definition and intervention. Diabetes Med. 2002;19:708–723
  43. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am. J. Kidney Dis. 1999;33:1004–1010
  44. Kissebah AH, Vydelingum N, Murray R, et al.  Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 1982;54:254–260
  45. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity on metabolism in men and women: importance of regional adipose tissue distribution. J. Clin. Invest. 1983;72:1150–1162
  46. Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med. Clin. North Am. 1989;73:111–138
  47. Pouliot MC, Després JP, Nadeau A. Visceral obesity in men: Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992;41:826–834

PII: S0168-8227(03)00257-2

doi: 10.1016/j.diabres.2003.10.001

Diabetes Research and Clinical Practice
Volume 64, Issue 1 , Pages 59-70 , April 2004

Article Tools

* Image Usage & Resolution